SHINE Medical (Janesville) is a company that will manufacture the medical isotope Mo-99 which is used in the diagnosis of the two biggest killers of Americans today: both heart disease and cancer. SHINE plans to build a plant in Janesville, WI to produce Mo-99 without the use of a nuclear reactor (the only current source for the isotopes). Over the course of its lifetime, it is expected that the products from this facility will have a positive impact on the lives of over 1 billion people. SHINE’s technology is greener, safer, and cheaper than existing production methods and addresses a massive and emerging global need.
In 2017, Shine was awarded $10 million funding from the National Nuclear Security Administration, part of the U.S. Department of Energy. They have now received a total of $25 million through this program. Shine says that some of the latest funding will be used for continued facility build, as well as to expand its engineering and business development teams. Shine has signed supply agreements with a number of large companies, including GE Healthcare, Lantheus Medical Imaging and HTA Co, a China based producer and distributor of radio-pharmaceuticals.
They also grew their team to 62 employees, the majority of whom are focusing on completing final design and engineering of the manufacturing facility and preparing for its construction. In addition, they constructed the first building on their site, Building One, which will demonstrate full-size production equipment later in 2018 and then become a technology development center.
For more information about SHINE Medical, see the news links below: